Eli Lilly and Company (LLY) Announces Results From Phase 3 BRUIN CLL-314 Trial Evaluating Jaypirca Versus Imbruvica

Eli Lilly and Company (NYSE:LLY) is one of the best pharma stocks to invest in. On December 7,  Eli Lilly and Company (NYSE:LLY) announced results from the Phase 3 BRUIN CLL-314 clinical trial that was evaluating Jaypirca (pirtobrutinib) versus Imbruvica (ibrutinib) in patients living with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who were either BTK inhibitor-naïve or treatment-naïve. Jaypirca is a non-covalent Bruton tyrosine kinase inhibitor, while Imbruvica is a covalent BTK ...